Merida Biosciences

Executive Summary

Merida Biosciences is a private biotechnology company headquartered in Cambridge, Massachusetts, dedicated to developing precision therapies for antibody-driven autoimmune diseases. Current treatments are non-specific, often exhibit poor efficacy, and carry significant safety risks. Merida's novel platform aims to selectively target and eliminate the pathogenic drivers of these diseases, offering unprecedented precision and durability. By addressing the root cause rather than symptoms, the company's approach has the potential to achieve durable clinical responses and transform the standard of care for patients with autoimmune disorders. The company is currently advancing its lead candidate through Phase 3 clinical trials, positioning it for potential near-term registration. Founded in 2024, Merida has rapidly progressed to late-stage development, reflecting strong execution and the promise of its platform. With a focus on high-unmet-need indications, the company is well-placed to deliver transformative therapies to patients. Successful Phase 3 data could support regulatory filings and attract strategic partnerships, further validating the platform and driving long-term growth.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Topline Data Readout65% success
• Q2 2027BLA Submission60% success
• H2 2026Strategic Partnership for Ex-US Rights50% success